دورية أكاديمية
Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Long-term AnTithrombotic TherApy-2 (REGATA)) ; Эффективность и безопасность ривароксабана у больных неклапанной фибрилляцией предсердий в реальной клинической практике (по данным регистра РЕГАТА-2)
| العنوان: | Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Long-term AnTithrombotic TherApy-2 (REGATA)) ; Эффективность и безопасность ривароксабана у больных неклапанной фибрилляцией предсердий в реальной клинической практике (по данным регистра РЕГАТА-2) |
|---|---|
| المؤلفون: | E. S. Kropacheva, E. N. Krivosheeva, E. P. Panchenko, Е. С. Кропачева, Е. Н. Кривошеева, Е. П. Панченко |
| المصدر: | Aterotromboz = Atherothrombosis; № 1 (2021); 68-88 ; Атеротромбоз; № 1 (2021); 68-88 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2021-1 |
| بيانات النشر: | «REMEDIUM GROUP» Ltd. |
| سنة النشر: | 2021 |
| المجموعة: | Atherothrombosis Journal / Атеротромбоз |
| مصطلحات موضوعية: | клинически значимые кровотечения, rivaroxaban, cardiovascular events, major bleedings, clinical relevant bleedings, ривароксабан, сердечно-сосудистые осложнения, крупные кровотечения |
| الوصف: | Introduction. Despite the large evidence base for the use of rivaroxaban, cohort studies are interesting because shows the possibility of anticoagulant therapy in patients with high thromboembolic and bleeding risk and a burden of comorbidity in practice.Aim: to evaluate the efficacy and safety of rivaroxaban therapy in patients with atrial fibrillation in prospective REGATTA registry.Materials and methods. This study is a fragment of a single-center prospective REGATA registry (Registry of Long-term Antithrombotic Therapy (NCT043447187), conducted on the basis of the National Research Center of Cardiology of the Ministry of Health of the Russian Federation. 152 patients with high thromboembolic risk (median CHA2DS2-VASc = 4) received rivaroxaban therapy (median follow-up 1.5 years). The efficacy endpoint was the sum of cardiovascular complications (including cardiovascular death, ischemic stroke, and acute coronary syndrome). The safety endpoint bleedinds BARC types 2-5.Results. The frequency of cardiovascular events (combining cardiovascular death, ischemic stroke and acute coronary syndrome) was 5.8/100 patient-years. The use of a “reduced” dose of rivaroxaban was an independent predictor of the development of fatal cardiovascular complications. The rate of major bleeding was 3.7/100 patient-years, and the rate of clinical relevant bleedings was 19.4 /100 patientyears. The predictors of major/ clinical relevant bleedings were chronic kidney disease with a decrease in creatinine clearance of less than 50 ml/min and the anamneses of major/ clinical relevant bleedings.Conclusion. The main requirement for improving the safety of anticoagulants is follow up, focused in all changes in the cardiovascular and somatic status of the patient during treatment. ; Введение. Несмотря на большую доказательную базу использования ривароксабана, представляют собой интерес когортные исследования как иллюстрация возможности антикоагулянтной терапии у больных высокого тромбоэмболического и геморрагического риска и высокой степени ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| العلاقة: | https://www.aterotromboz.ru/jour/article/view/245/267Test; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612Test.; January C.T., Wann L.S., Calkins H., Chen L.Y., Cigarroa J.E., Cleveland J.C. Jr et al. 2019 AHA/ ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151. https://doi.org/10.1016/j.jacc.2019.01.011Test.; McIntyre W. F., Conen D., Olshansky B., Halperin J.L., Hayek E., Huisman M.V. et al. Stroke-Prevention Strategies in North American Patients with Atrial Fibrillation: The GLORIA-AF Registry Program. Clin Cardiol. 2018;41(6):744–751. https://doi.org/10.1002/clc.22936Test.; Steinberg B.A., Gao H., Shrader P., Pieper K., Thomas L., Camm A.J. et al. International Trends in Clinical Characteristics and Oral Anticoagulation Treatment for Patients with Atrial Fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II Registries. Am Heart J. 2017;194:132–140. https://doi.org/10.1002/clc.22936Test.; Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D. et al. Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials. Lancet. 2014;383(9921):955–962. https://doi.org/10.1016/S0140-6736Test(13)62343-0.; Patti G., Pecen L., Lucerna M., Huber K., Rohla M., Renda G. et al. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. Am J Med. 2019;132(6):749.e5-757.e5. https://doi.org/10.1016/j.amjmed.2018.12.036Test.; Testa S., Ageno W., Antonucci E., Morandini R., BeyerWestendorf J., Paciaroni M. et al. Management of Major Bleeding and Outcomes in Patients Treated with Direct Oral Anticoagulants: Results from the STARTEvent Registry. Intern Emerg Med. 2018;13(7):1051– 1058. https://doi.org/10.1007/s11739-018-1877-zTest.; Becattini C., Franco L., Beyer-Westendorf J., Masotti L., Nitti C., Vanni S. et al. Major Bleeding with Vitamin K Antagonists or Direct Oral Anticoagulants in Real-Life. Int J Cardiol. 2017;227:261–266. https://doi.org/10.1016/j.ijcard.2016.11.117Test.; Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W. et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–891. https://doi.org/10.1056/NEJMoa1009638Test.; Beyer-Westendorf J., Förster K., Pannach S., Ebertz F., Gelbricht V., Thieme C. et al. Rates, Management, and Outcome of Rivaroxaban Bleeding in Daily Care: Results from the Dresden NOAC Registry. Blood. 2014;124(6):955–962. https://doi.org/10.1182/blood2014-03-563577Test.; Hecker J., Marten S., Keller L., Helmert S., Michalski F., Werth S. et al. Effectiveness and Safety of Rivaroxaban Therapy in Daily-Care Patients with Atrial Fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2016;115(5):939–949. https://doi.org/10.1160/TH15-10-0840Test.; Camm A.J., Amarenco P., Haas S., Hess S., Kirchhof P., Kuhls S. et al. XANTUS: A Real-World, Prospective, Observational Study of Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. Eur Heart J. 2016;37(14):1145–1153. https://doi.org/10.1093/eurheartj/ehv466Test.; Tamayo S., Frank Peacock W., Patel M., Sicignano N., Hopf K.P., Fields L.E. et al. Characterizing Major Bleeding in Patients with Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban. Clin Cardiol. 2015;38(2):63–68. https://doi.org/10.1002/clc.22373Test.; Steg P.G., Huber K., Andreotti F., Arnesen H., Atar D., Badimon L. et al. Bleeding in Acute Coronary Syndromes and Percutaneous Coronary Interventions: Position Paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854–1864. https://doi.org/10.1093/eurheartj/ehr204Test.; Beyer-Westendorf J., Förster K., Ebertz F., Gelbricht V., Schreier T., Göbelt M. et al. Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation PatientsResults from the Dresden Non-Interventional Oral Anticoagulation Registry. Europace. 2015;17(4):530– 538. https://doi.org/10.1093/europace/euu319Test.; Alberts M., Chen Y.W., Lin J.H., Kogan E., Twyman K., Milentijevic D. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin. Stroke. 2020;51(2):549–555. https://doi.org/10.1161/STROKEAHA.119.025554Test.; Kitazono T., Ikeda T., Ogawa S., Nakagawara J., Minematsu K., Miyamoto S. et al. Real-World Outcomes of Rivaroxaban Treatment in Elderly Japanese Patients with Nonvalvular Atrial Fibrillation. Heart Vessels. 2020;35(3):399–408. https://doi.org/10.1007/s00380-019-01487-xTest.; Miyamoto S., Ikeda T., Ogawa S., Kitazono T., Nakagawara J., Minematsu K. et al. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan. J Stroke Cerebrovasc Dis. 2020;29(4):104584. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104584Test.; Berg D.D., Ruff C.T., Jarolim P., Giugliano R.P., Nordio F., Lanz H.J. et al. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019;139(6):760–771. https://doi.org/10.1161/CIRCULATIONAHA.118.038312Test.; Wallentin L., Hijazi Z., Andersson U., Alexander J.H., De Caterina R., Hanna M. et al. Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients with Atrial Fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2014;130(21):1847–1858. https://doi.org/10.1161/CIRCULATIONAHA.114.011204Test.; Hagström E., James S.K., Bertilsson M., Becker R.C., Himmelmann A., Husted S. et al. Growth Differentiation Factor-15 Level Predicts Major Bleeding and Cardiovascular Events in Patients with Acute Coronary Syndromes: Results from the PLATO Study. Eur Heart J. 2016;37(16):1325–1333. https://doi.org/10.1093/eurheartj/ehv491Test.; Ruff C.T., Giugliano R.P., Braunwald E., Murphy S.A., Brown K., Jarolim P. et al. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2016;1(9):999–1006. https://doi.org/10.1001/jamacardio.2016.3311Test.; Christersson C., Wallentin L., Andersson U., Alexander J.H., Ansell J., De Caterina R. et al. D-Dimer and Risk of Thromboembolic and Bleeding Events in Patients with Atrial Fibrillation – Observations from the ARISTOTLE Trial. J Thromb Haemost. 2014;12(9):1401–1412. https://doi.org/10.1111/jth.12638Test.; Hijazi Z., Oldgren J., Siegbahn A., Wallentin L. Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. Clin Chem. 2017;63(1):152–164. https://doi.org/10.1373/clinchem.2016.255182Test.; Steinberg B.A., Shrader P., Pieper K., Thomas L., Allen L.A., Ansell J. et al. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc. 2018;7(4):e007633. https://doi.org/10.1161/JAHA.117.007633Test.; Staerk L., Gerds T.A., Lip G.Y. H., Ozenne B., Bonde A.N., Lamberts M. et al. Standard and Reduced Doses of Dabigatran, Rivaroxaban and Apixaban for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study. J Intern Med. 2018;283(1):45–55. https://doi.org/10.1111/joim.12683Test.; Arbel R., Sergienko R., Hammerman A., GreenbergDotan S., Batat E., Avnery O., Ellis M.H. Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. Am J Med. 2019;132(7):847.e3-855.e3. https://doi.org/10.1016/j.amjmed.2019.01.025Test.; Xing L.Y., Barcella C.A., Sindet-Pedersen C., Bonde A.N., Gislason G.H., Olesen J.B. Dose Reduction of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation: A Danish Nationwide Cohort Study. Thromb Res. 2019;178:101–109. https://doi.org/10.1016/j.thromres.2019.04.007Test.; Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L. et al. The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Eur Heart J. 2018;39(16):1330–1393. https://doi.org/10.1093/eurheartj/ehy136Test.; Haim M., Hoshen M., Reges O., Rabi Y., Balicer R., Leibowitz M. Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients with Incident Non-Valvular Atrial Fibrillation. J Am Heart Assoc. 2015;4(1):e001486. https://doi.org/10.1161/JAHA.114.001486Test.; Kirchhof P., Ammentorp B., Darius H., De Caterina R., Le Heuzey J.Y., Schilling R.J. et al. Management of Atrial Fibrillation in Seven European Countries after the Publication of the 2010 ESC Guidelines on Atrial Fibrillation: Primary Results of the PREvention oF Thromboemolic Events – European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6– 14. https://doi.org/10.1093/europace/eut263Test.; Kralev S., Schneider K., Lang S., Süselbeck T., Borggrefe M. Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography. PLoS ONE. 2011;6(9):e24964. https://doi.org/10.1371/journal.pone.0024964Test.; Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa F., Jeppsson A. et al. 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–260. https://doi.org/10.1093/eurheartj/ehx419Test.; Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U. et al. 2018 ESC/EACTS Guidelines on Myocardial Revascularization. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394Test.; Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210Test.; Gibson C.M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423– 2434. https://doi.org/10.1056/NEJMoa1611594Test.; Lip G.Y. H., Collet J.P., Haude M., Byrne R., Chung E.H., Fauchier L. et al. 2018 Joint European Consensus Document on the Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Cardiovascular Interventions: A Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) Endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21(2):192–193. https://doi.org/10.1093/europace/euy174Test.; Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. Eur Heart J. 2020;41(3):407–477. https://doi.org/10.1093/eurheartj/ehz425Test.; Кривошеева Е.Н., Панченко Е.П., Кропачева Е.С., Добровольский А.Б., Титаева Е.В., Миронов В.М., Самко А.Н. Исходы, определяющие прогноз, и их предикторы у больных фибрилляцией предсердий, получающих многокомпонентную антитромботическую терапию в условиях клинической практики. Кардиология. 2020;60(8):33–45. https://doi.org/10.18087/cardio.2020.8.n1123Test.; Ikeda T., Ogawa S., Kitazono T., Nakagawara J., Minematsu K., Miyamoto S. et al. Real-World Outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS). J Cardiol. 2019;74(1):60–66. https://doi.org/10.1016/j.jjcc.2019.01.001Test.; Волкова Э.Г., Драпкина О.М., Еганян Р.А., Кисляк О.М., Кобалава Ж.Д., Колтунов И.Е. и др. Кардиоваскулярная профилактика: национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;6(Прил. 2):1–64. Режим доступа: https://scardio.ru/content/images/recommendation/nacionalnye_rekomendacii_po_kardiovaskulyarnoy_profilaktike.pdfTest.; Soliman E.Z., Prineas R.J., Go A.S., Xie D., Lash J.P., Rahman M. et al. Chronic Kidney Disease and Prevalent Atrial Fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159(6):1102–1107. https://doi.org/10.1016/j.ahj.2010.03.027Test.; Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int. 2013;3(Suppl.):259–305. Available at: https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2013-Lipids-Guideline-English.pdfTest.; Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M. et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219. https://doi.org/10.1093/eurheartj/eht151Test.; Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M. et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of Nine Societies and by Invited Experts). Eur Heart J. 2012;33(13):1635–1701. https://doi.org/10.1093/eurheartj/ehs092Test.; Землянская О.А., Кропачева Е.С., Добровольский А.Б., Панченко Е.П. Функция почек у больных, длительно принимающих варфарин (5-летнее проспективное наблюдение). Терапевтический архив. 2017;89(9):78–86. https://doi.org/10.17116/terarkh201789978-86Test.; Fang M.C., Go A.S., Chang Y., Borowsky L.H., Pomernacki N.K., Udaltsova N., Singer D.E. A New Risk Scheme to Predict Warfarin-Associated Hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395– 401. https://doi.org/10.1016/j.jacc.2011.03.031Test.; O’Brien E.C., Simon D.N., Thomas L.E., Hylek E.M., Gersh B.J., Ansell J.E. et al. The ORBIT Bleeding Score: A Simple Bedside Score to Assess Bleeding Risk in Atrial Fibrillation. Eur Heart J. 2015;36(46):3258– 3264. https://doi.org/10.1093/eurheartj/ehv476Test.; Lip G.Y. H., Skjøth F., Nielsen P.B., Kjældgaard J.N., Larsen T.B. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using NonVitamin K Antagonist Oral Anticoagulants. Am J Med. 2018;131(5):574.e13-574.e27. https://doi.org/10.1016/j.amjmed.2017.11.046Test.; Olesen J.B., Lip G.Y., Kamper A.L., Hommel K., Køber L., Lane D.A. et al. Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. N Engl J Med. 2012;367(7):625–635. https://doi.org/10.1056/NEJMoa1105594Test.; Godino C., Melillo F., Rubino F., Arrigoni L., Cappelletti A., Mazzone P. et al. Real-World 2-Year Outcome of Atrial Fibrillation Treatment with Dabigatran, Apixaban, and Rivaroxaban in Patients with and without Chronic Kidney Disease. Intern Emerg Med. 2019;14(8):1259–1270. https://doi.org/10.1007/s11739-019-02100-9Test.; Goodman S.G., Wojdyla D.M., Piccini J.P., White H.D., Paolini J.F., Nessel C.C. et al. Factors Associated with Major Bleeding Events: Insights from the ROCKET AF Trial (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(9):891–900. https://doi.org/10.1016/j.jacc.2013.11.013Test.; Halvorsen S., Storey R.F., Rocca B., Sibbing D., Ten Berg J., Grove E.L. et al. Management of Antithrombotic Therapy after Bleeding in Patients with Coronary Artery Disease and/or Atrial Fibrillation: Expert Consensus Paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017;38(19):1455–1462. https://doi.org/10.1093/eurheartj/ehw454Test.; Little D., Chai-Adisaksopha C., Hillis C., Witt D.M., Monreal M., Crowther M.A., Siegal D.M. Resumption of Anticoagulant Therapy after Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Thromb Res. 2019;175:102–109. https://doi.org/10.1016/j.thromres.2019.01.020Test.; Chai-Adisaksopha C., Hillis C., Monreal M., Witt D.M., Crowther M. Thromboembolic Events, Recurrent Bleeding and Mortality after Resuming Anticoagulant Following Gastrointestinal Bleeding. A Meta-Analysis. Thromb Haemost. 2015;114(4):819–825. https://doi.org/10.1160/TH15-01-0063Test.; https://www.aterotromboz.ru/jour/article/view/245Test |
| DOI: | 10.21518/2307-1109-2021-1-68-88 |
| الإتاحة: | https://doi.org/10.21518/2307-1109-2021-1-68-88Test https://doi.org/10.21518/2307-1109-2021-1Test https://doi.org/10.1093/eurheartj/ehaa612Test https://doi.org/10.1016/j.jacc.2019.01.011Test https://doi.org/10.1002/clc.22936Test https://doi.org/10.1016/S0140-6736Test(13)62343-0 https://doi.org/10.1016/j.amjmed.2018.12.036Test https://doi.org/10.1007/s11739-018-1877-zTest https://doi.org/10.1016/j.ijcard.2016.11.117Test https://doi.org/10.1056/NEJMoa1009638Test |
| حقوق: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution Attribution-NonCommercial-NoDerivs License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.C2668924 |
| قاعدة البيانات: | BASE |
| DOI: | 10.21518/2307-1109-2021-1-68-88 |
|---|